New Pill Shows Promise in Lowering Cholesterol, Reducing Heart Disease Risk
For millions of Americans grappling with high cholesterol, a new oral medication called enlicitide is offering a beacon of hope. While statins remain a primary treatment, many individuals don’t achieve desired cholesterol levels even with these drugs. Enlicitide, an experimental PCSK9 inhibitor, could provide a more effective and convenient alternative to current injectable options.
Understanding the Problem: Cholesterol and Heart Disease
Heart disease is the leading cause of death in the United States, and high levels of low-density lipoprotein (LDL) cholesterol – often referred to as “bad” cholesterol – play a significant role in its development. LDL cholesterol contributes to the buildup of plaque in the arteries, a process known as atherosclerosis, which can lead to heart attack, and stroke. Cleveland Clinic explains that blood tests can help healthcare providers assess heart disease risk by examining cholesterol levels.
How Enlicitide Works
Currently, individuals who require more intensive cholesterol-lowering therapy often rely on injectable PCSK9 inhibitors. These medications are effective but can be expensive and inconvenient. Enlicitide offers a potential solution as an oral PCSK9 inhibitor, aiming to block the production of cholesterol in a more accessible format.
Study Results: Significant Cholesterol Reduction
A recent study conducted at UT Southwestern Medical Center and published in the New England Journal of Medicine involved over 2,909 high-risk participants. The study, a blinded trial, assigned half of the participants to take a daily enlicitide pill while the other half received a placebo alongside their standard treatment. According to Worth a look